Literature DB >> 17372135

Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.

M G Chheda1, J Drappatz, N J Greenberger, S Kesari, S E Weiss, D C Gigas, L M Doherty, P Y Wen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17372135     DOI： 10.1212/01.wnl.0000259430.48835.b5

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  11 in total

1.  Temozolomide-induced liver damage. A case report.

Authors:  F Becker; M Hecht; J Schmidtner; S Semrau; R Fietkau
Journal:  Strahlenther Onkol       Date:  2014-01-24       Impact factor: 3.621

Review 2.  Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.

Authors:  Giselle Sarganas; Hans D Orzechowski; Andreas Klimpel; Michael Thomae; Wolfgang Kauffmann; Hermann Herbst; Elisabeth Bronder; Edeltraut Garbe
Journal:  Neuro Oncol       Date:  2012-03-06       Impact factor: 12.300

3.  North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.

Authors:  Jann N Sarkaria; Evanthia Galanis; Wenting Wu; Patrick J Peller; Caterina Giannini; Paul D Brown; Joon H Uhm; Steven McGraw; Kurt A Jaeckle; Jan C Buckner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-23       Impact factor: 7.038

4.  Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis.

Authors:  Yasunori Fujimoto; Naoya Hashimoto; Manabu Kinoshita; Yuko Miyazaki; Satoshi Tanaka; Takayuki Yakushijin; Tetsuo Takehara; Naoki Kagawa; Toshiki Yoshimine
Journal:  Int J Clin Oncol       Date:  2011-08-03       Impact factor: 3.402

Review 5.  Medical management of brain tumors and the sequelae of treatment.

Authors:  David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-10-30       Impact factor: 12.300

6.  Hepatitis B virus reactivation during temozolomide administration for malignant glioma.

Authors:  Takuhiro Shoji; Masayuki Kanamori; Jun Inoue; Ryuta Saito; Yoshinari Osada; Yoshiteru Shimoda; Masashi Chonan; Hiroshi Uenohara; Atsushi Masamune; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2020-10-28       Impact factor: 3.402

7.  Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.

Authors:  Marcus Niewald; Christian Berdel; Jochen Fleckenstein; Norbert Licht; Ralf Ketter; Christian Rübe
Journal:  Radiat Oncol       Date:  2011-10-21       Impact factor: 3.481

Review 8.  Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.

Authors:  Antonio Grieco; Maria Antonietta Tafuri; Marco Biolato; Barbara Diletto; Nicola Di Napoli; Nicola Balducci; Fabio Maria Vecchio; Luca Miele
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

9.  Hepatitis B Reactivation After Ifosfamide Therapy for Retroperitoneal Sarcoma.

Authors:  Purva Chhibar; Ziqiang Zhu; Naga K S Cheedella; Rashid Chaudhry; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2016-06-01

10.  Disseminated strongyloidiasis complicating glioblastoma therapy: a case report.

Authors:  Dawit Aregawi; David Lopez; Mark Wick; W Michael Scheld; David Schiff
Journal:  J Neurooncol       Date:  2009-03-31       Impact factor: 4.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.